GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portola Pharmaceuticals Inc (NAS:PTLA) » Definitions » Profitability Rank

Portola Pharmaceuticals (Portola Pharmaceuticals) Profitability Rank : 0 (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Portola Pharmaceuticals Profitability Rank?

Portola Pharmaceuticals has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Portola Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 was -221.45%. As of today, Portola Pharmaceuticals's Piotroski F-Score is 0.


Competitive Comparison of Portola Pharmaceuticals's Profitability Rank

For the Biotechnology subindustry, Portola Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portola Pharmaceuticals's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portola Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Portola Pharmaceuticals's Profitability Rank falls into.



Portola Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Portola Pharmaceuticals has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Portola Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2020 ) / Revenue (Q: Mar. 2020 )
=-58.438 / 26.389
=-221.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Portola Pharmaceuticals has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Portola Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Portola Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Portola Pharmaceuticals (Portola Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
270 E. Grand Avenue, South San Francisco, CA, USA, 94080
Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.
Executives
Dennis M Fenton director
John B Moriarty officer: EVP, General Counsel ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Hollings Renton director
David C Stump director
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Jeffrey W Bird director 755 PAGE MILL RD STE A-200, PALO ALTO CA 94304-1005
Henry Ward Wolff director 6701 KAISER DRIVE, FREMONT CA 94555
J. Scott Garland director, officer: President and CEO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Mardi Dier officer: EVP and CFO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Rajiv Patni officer: EVP, CMO C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
John T Curnutte officer: EVP R&D PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Charles J Homcy other: Former Director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
William Lis director, officer: Chief Executive Officer PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080

Portola Pharmaceuticals (Portola Pharmaceuticals) Headlines

From GuruFocus